Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			After hours 23:10:43
303.05 ^USD	-0.19%		294.96	-2.67%

06-03	Alnylam, Inceptive sign up to $2 billion AI drug discovery deal	RE
06-03	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics	MT

Transcript : Alnylam Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 10

Published on 05/13/2026 at 08:35 pm BST - Modified on 05/13/2026 at 09:50 pm BST

S&P Capital IQ

Presenter Speech
Tazeen Ahmad (Analysts)

Good morning. I'm Tazeen Ahmad. I'm one of the senior biotech analysts at the bank. It's my pleasure to have our next presenting company with us, Alnylam

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Alnylam Pharmaceuticals, Inc.

06-03	Alnylam, Inceptive sign up to $2 billion AI drug discovery deal	RE
06-03	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics	MT
06-03	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics	CI
05-27	Alnylam Pharmaceuticals, Inc. Elects Benjamin F. Cravatt as Class III Director and Member of Board?s Science and Technology Committee, Effective as of June 1, 2026	CI
05-13	Alnylam Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 10:40 AM
05-12	Alnylam Pharmaceuticals, Inc. Announces New Analyses from the Helios-B Phase 3 Study of Vutrisiran in Patients	CI
05-01	RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating	MT
04-30	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Alnylam Pharmaceuticals, Inc., Q1 2026 Earnings Call, Apr 30, 2026
04-30	Alnylam Pharmaceuticals Q1 Adjusted Net Income, Revenue Rise; Reiterates 2026 Product Revenue Guidance -- Shares Up Pre-Bell	MT
04-30	(ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.90B - $5.30B	MT
04-30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q1 Revenue $1.17B, vs. FactSet Est of $1.12B	MT
04-30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $1.99 per Share	MT
04-06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
03-30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI